BACKGROUND: Smooth muscle cells proliferation and extracellular matrix (ECM) protein deposition are key features of diabetic macroangiopathy. In the present study, we have studied the role of endothelin(A) (ET(A)) receptor, the predominant receptor on smooth muscle cells, in diabetes-induced vascular hypertrophy and remodeling. METHODS: Streptozotocin-induced diabetic rats were administrated a selective ET(A) receptor antagonist, TBC3214, for 26 weeks. Following treatment, aortas were harvested and subjected to gene expression and morphometric analyses. We quantified fibronectin (FN) and plasminogen activator inhibitor-1 (PAI-1) expression as indicators of increased ECM protein synthesis. ET-1, ET-3, transforming growth factor-beta1 (TGF-beta1) and angiotensinogen mRNA levels were measured to elucidate genes involved in FN expression. We have investigated an embryonic splice variant of FN, oncofetal FN, and nonmuscle myosin heavy chain (SMemb) as vascular remodeling indicators. RESULTS: Our results show that diabetes leads to upregulation of FN, PAI-1, ET-1, ET-3, TGF-beta1 and angiotensinogen mRNA levels in association with increased medial thickness. Immunohistochemical analyses revealed concurrent protein level changes. Diabetes also upregulated oncofetal FN and SMemb mRNA levels. Treatment with TBC3214 attenuated the mRNA levels of several genes and prevented increased medial thickness. CONCLUSIONS: These results indicate that diabetes-induced vascular hypertrophy and remodeling is associated with reexpression of embryonic forms of FN and myosin heavy chain. Such changes are ET-dependent and may be mediated via TGF-beta1 and angiotensin.
BACKGROUND: Smooth muscle cells proliferation and extracellular matrix (ECM) protein deposition are key features of diabetic macroangiopathy. In the present study, we have studied the role of endothelin(A) (ET(A)) receptor, the predominant receptor on smooth muscle cells, in diabetes-induced vascular hypertrophy and remodeling. METHODS:Streptozotocin-induced diabeticrats were administrated a selective ET(A) receptor antagonist, TBC3214, for 26 weeks. Following treatment, aortas were harvested and subjected to gene expression and morphometric analyses. We quantified fibronectin (FN) and plasminogen activator inhibitor-1 (PAI-1) expression as indicators of increased ECM protein synthesis. ET-1, ET-3, transforming growth factor-beta1 (TGF-beta1) and angiotensinogen mRNA levels were measured to elucidate genes involved in FN expression. We have investigated an embryonic splice variant of FN, oncofetal FN, and nonmuscle myosin heavy chain (SMemb) as vascular remodeling indicators. RESULTS: Our results show that diabetes leads to upregulation of FN, PAI-1, ET-1, ET-3, TGF-beta1 and angiotensinogen mRNA levels in association with increased medial thickness. Immunohistochemical analyses revealed concurrent protein level changes. Diabetes also upregulated oncofetal FN and SMemb mRNA levels. Treatment with TBC3214 attenuated the mRNA levels of several genes and prevented increased medial thickness. CONCLUSIONS: These results indicate that diabetes-induced vascular hypertrophy and remodeling is associated with reexpression of embryonic forms of FN and myosin heavy chain. Such changes are ET-dependent and may be mediated via TGF-beta1 and angiotensin.
Authors: Chris J Sullivan; Thomas H Teal; Ian P Luttrell; Khoa B Tran; Mette A Peters; Hunter Wessells Journal: Physiol Genomics Date: 2005-08-23 Impact factor: 3.107
Authors: Kamakshi Sachidanandam; Jim R Hutchinson; Mostafa M Elgebaly; Erin M Mezzetti; Anne M Dorrance; Kouros Motamed; Adviye Ergul Journal: Am J Physiol Regul Integr Comp Physiol Date: 2009-01-28 Impact factor: 3.619
Authors: A M D Watson; J Li; C Schumacher; M de Gasparo; B Feng; M C Thomas; T J Allen; M E Cooper; K A M Jandeleit-Dahm Journal: Diabetologia Date: 2009-10-28 Impact factor: 10.122
Authors: Mostafa M Elgebaly; Aisha Kelly; Alex K Harris; Hazem Elewa; Vera Portik-Dobos; Pimonrat Ketsawatsomkron; Mario Marrero; Adviye Ergul Journal: Can J Physiol Pharmacol Date: 2008-06 Impact factor: 2.273
Authors: Erik Salum; Mark Butlin; Jaak Kals; Mihkel Zilmer; Jaan Eha; Alberto P Avolio; Andres Arend; Marina Aunapuu; Priit Kampus Journal: Diabetol Metab Syndr Date: 2014-05-20 Impact factor: 3.320